# COVID-19 and Anti-CD14 Treatment Trial

> **NCT04391309** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 49 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

## Interventions

- **BIOLOGICAL:** anti-CD14
- **OTHER:** Placebo
- **DRUG:** remdesivir

## Key facts

- **NCT ID:** NCT04391309
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-12
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Stopped to slow rate of enrollment
- **Last updated:** 2023-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391309, "COVID-19 and Anti-CD14 Treatment Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04391309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*